Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Chimera Biotec logo — GLP / GCP Bioanalytical CRO – ultra sensitive Immunoassays

Chimera Biotec

GLP / GCP Bioanalytical CRO – ultra sensitive Immunoassays

Founded 2000 Germany Bremen, Germany 19 employees Biotechnology, Life Sciences

General Information

Company Name Chimera Biotec
Founded Year 2000
Location Germany Bremen, Germany +2
Employees 19
Industries Biotechnology, Life Sciences
Social

Get notified when Chimera Biotec moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Chimera Biotec

Chimera Biotec is a German biotechnology company specializing in bioanalysis and ultra-sensitive immunoassay services. With over 20 years of experience, the company offers GLP/GCP bioanalytical support for all phases of drug discovery and development, particularly focusing on high demands for bioanalytical quality. Their expertise lies in the development, validation, and support of immunoassays, going beyond traditional ELISA methods with platforms such as Imperacer (Immuno-PCR), Simoa® (Quanterix), MSD, and high sensitivity ELISA. Chimera Biotec's unique approach allows clients to leverage their in-house platforms and only outsource specific case studies where improved sensitivities are required. The company works closely with clients, offering technology evaluation studies to select the ideal platform for each study, tailored to their individual expectations. Whether it's non-regulated discovery phase or GCP clinical phase support, or IND-enabling TOX under full GLP-regime, Chimera Biotec ensures the method validation aligns with the expectations of bioanalytical support, catering to various dosage levels and clinical stages. This 20-year-old company presents an opportunity for investors seeking to tap into the growing demand for bioanalytical services in the biotechnology industry. With its strong focus on immunoassay excellence and support for drug development programs, Chimera Biotec demonstrates the potential for growth and innovation in the evolving biotech sector.

Taxonomy: Bioanalytical services, Immunoassays, GLP/GCP compliance, Drug development support, Ultra-sensitive assays, Imperacer® technology, Assay development, Method validation, PK/PD sample testing, Simoa Quanterix, High sensitivity ELISA, Biotherapeutics support, Biomarker testing, Immunogenicity testing

No funding data available for Chimera Biotec yet.

Get notified when Chimera Biotec raises funding

FAQ About Chimera Biotec

GLP / GCP Bioanalytical CRO – ultra sensitive Immunoassays
Chimera Biotec was founded in 2000.
Chimera Biotec is headquartered in Bremen, Germany.
Chimera Biotec operates in the following industries: Biotechnology, Life Sciences.
Chimera Biotec has approximately 19 employees.

We're actively collecting intelligence on Chimera Biotec.

Track Chimera Biotec to get notified

Don't just browse. Track.

Signal Tracker monitors Chimera Biotec and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy